Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Do you hold endocrine therapy during adjuvant breast radiotherapy?
Are there additional risks associated with PMRT for a patient with prior lympho-venous bypass surgery?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
When using FAST Forward, how important is it for the treatment to be delivered Monday through Friday in one week as opposed to spanning a weekend?
What are your top takeaways in Breast Cancer from ASTRO 2024?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
In a patient with cardiac comorbidities, who meets ASTRO APBI criteria other than a positive margin, would you offer APBI in an attempt to reduce cardiac dose?
What are your top takeaways in Medical Oncology from SABCS 2024?
